Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;27(5):295-301.
doi: 10.1097/MOH.0000000000000600.

Nonsevere hemophilia A: often overlooked, but not forgotten

Ming Y Lim  1 , Tyler W Buckner  2
Affiliations
Review

Nonsevere hemophilia A: often overlooked, but not forgotten

Ming Y Lim et al. Curr Opin Hematol. 2020 Sep.

Abstract

Purpose of review: Nonsevere hemophilia A (NSHA) patients have received relatively little clinical and research attention as compared with their severe counterparts. There is increasing recognition that despite their milder bleeding phenotype, the management of NSHA can be a challenge, with most management decisions largely inferred from severe hemophilia A data. This review focuses on some of the more recent developments in the field of NSHA.

Recent findings: Epidemiologic studies suggest that NSHA remain under-recognized and under-diagnosed globally. As the NSHA population ages, they are susceptible to age-related comorbidities. Large cohort studies of NSHA report that the most common primary cause of death is malignancy. NSHA patients have a lifetime risk of inhibitor development with increasing exposure to factor VIII concentrate. Even so, not all patients with inhibitors will require eradication treatment, irrespective of bleeding phenotype at time of inhibitor development.

Summary: As there are currently no evidence-based strategies for inhibitor eradication in NSHA patients, preventive strategies are critical to mitigate inhibitor risk in NSHA. There is a need for active surveillance of NSHA patients by hemophilia treatment centers to address hemophilia-related issues and other age-related comorbidities, in collaboration with primary care physicians and other subspecialists.

PubMed Disclaimer

References

    1. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med 2019; 171:540–546.
    1. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia 2013; 19:e1–e47.
    1. Soucie JM, Miller CH, Dupervil B, et al. Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres. Haemophilia 2020; 26:487–493.
    1. World Federation of Hemophilia. Report on the annual global survey 2018. Available at www.wfh.org/publications/files/pdf-1731.pdf. [Accessed on 15 May 2019].
    1. Centers for Disease Control and Prevention. HTC population profile patient characteristics, factor VIII and factor IX deficiencies, data reported from 1/1/2012 through 09/29/2019. Atlanta, GA: Centers for Disease Control and Prevention; 2020.

Publication types